0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Idiopathic Pulmonary Fibrosis Market Insights, Forecast to 2029
Published Date: August 2023
|
Report Code: QYRE-Auto-8O6240
Home | Market Reports | Health| Health Conditions| Respiratory Conditions
Global Idiopathic Pulmonary Fibrosis Market Size Status and Forecast 2021 2027
BUY CHAPTERS

Global Idiopathic Pulmonary Fibrosis Market Insights, Forecast to 2029

Code: QYRE-Auto-8O6240
Report
August 2023
Pages:91
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Idiopathic Pulmonary Fibrosis Market Size

The global Idiopathic Pulmonary Fibrosis market is projected to grow from US$ 1956.9 million in 2023 to US$ 3373.4 million by 2029, at a Compound Annual Growth Rate (CAGR) of 9.5% during the forecast period.

Idiopathic Pulmonary Fibrosis Market

Idiopathic Pulmonary Fibrosis Market

Idiopathic pulmonary fibrosis is a condition in which the tissues in the lungs become thick and stiff over time. As a result of thickening of lung tissues, brain and other organs are unable receive optimum oxygen.
Market Analysis and Insights: Global Idiopathic Pulmonary Fibrosis Market
An increase in the incidence and prevalence of fibrotic diseases is the primary driver for the growth of this market. Idiopathic pulmonary fibrosis most commonly affects middle-aged to older adults and is characterized by the scarring of lung tissues. In older people, these scars tend to build up and affect the normal functioning of lungs. Thus, an increase in aging population leads to increased prevalence of the disease, which in turn results in market growth during the predicted period.
Report Includes
This report presents an overview of global market for Idiopathic Pulmonary Fibrosis market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Idiopathic Pulmonary Fibrosis, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Idiopathic Pulmonary Fibrosis, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Idiopathic Pulmonary Fibrosis revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Idiopathic Pulmonary Fibrosis market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Idiopathic Pulmonary Fibrosis revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including MediciNova, Boehringer Ingelheim, F. Hoffmann-La Roche, FibroGen, Promedior, Merck, Galapagos, Prometic Life Sciences and Cipla, etc.

Scope of Idiopathic Pulmonary Fibrosis Market Report

Report Metric Details
Report Name Idiopathic Pulmonary Fibrosis Market
Accounted market size in 2023 US$ 1956.9 million
Forecasted market size in 2029 US$ 3373.4 million
CAGR 9.5
Base Year 2023
Forecasted years 2023 - 2029
Segment by Type
  • Systemic Corticosteroids
  • Immunosuppressant Drugs
  • Tyrosine Kinase Inhibitors
  • Antifibrotic Agents
Segment by Application
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Academic and Research Organizations
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company MediciNova, Boehringer Ingelheim, F. Hoffmann-La Roche, FibroGen, Promedior, Merck, Galapagos, Prometic Life Sciences, Cipla
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Revenue of Idiopathic Pulmonary Fibrosis in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Idiopathic Pulmonary Fibrosis companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: North America by type, by application and by country, revenue for each segment.
  • Chapter 7: Europe by type, by application and by country, revenue for each segment.
  • Chapter 8: China by type and by application revenue for each segment.
  • Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
  • Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
  • Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Idiopathic Pulmonary Fibrosis revenue, gross margin, and recent development, etc.
  • Chapter 12: Analyst's Viewpoints/Conclusions

FAQ for this report

How fast is Idiopathic Pulmonary Fibrosis Market growing?

Ans: The Idiopathic Pulmonary Fibrosis Market witnessing a CAGR of 9.5 during the forecast period 2023-2029.

What is the Idiopathic Pulmonary Fibrosis Market size in 2029?

Ans: The global Idiopathic Pulmonary Fibrosis market is projected to grow from US$ 1956.9 million in 2023 to US$ 3373.4 million by 2029, at a Compound Annual Growth Rate (CAGR) of 9.5% during the forecast period.

Who are the main players in the Idiopathic Pulmonary Fibrosis Market report?

Ans: The main players in the Idiopathic Pulmonary Fibrosis Market are MediciNova, Boehringer Ingelheim, F. Hoffmann-La Roche, FibroGen, Promedior, Merck, Galapagos, Prometic Life Sciences, Cipla

What are the Application segmentation covered in the Idiopathic Pulmonary Fibrosis Market report?

Ans: The Applications covered in the Idiopathic Pulmonary Fibrosis Market report are Hospitals, Clinics, Ambulatory Surgical Centers, Academic and Research Organizations

What are the Type segmentation covered in the Idiopathic Pulmonary Fibrosis Market report?

Ans: The Types covered in the Idiopathic Pulmonary Fibrosis Market report are Systemic Corticosteroids, Immunosuppressant Drugs, Tyrosine Kinase Inhibitors, Antifibrotic Agents

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Idiopathic Pulmonary Fibrosis Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Systemic Corticosteroids
1.2.3 Immunosuppressant Drugs
1.2.4 Tyrosine Kinase Inhibitors
1.2.5 Antifibrotic Agents
1.3 Market by Application
1.3.1 Global Idiopathic Pulmonary Fibrosis Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Academic and Research Organizations
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Idiopathic Pulmonary Fibrosis Market Perspective (2018-2029)
2.2 Global Idiopathic Pulmonary Fibrosis Growth Trends by Region
2.2.1 Idiopathic Pulmonary Fibrosis Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Idiopathic Pulmonary Fibrosis Historic Market Size by Region (2018-2023)
2.2.3 Idiopathic Pulmonary Fibrosis Forecasted Market Size by Region (2024-2029)
2.3 Idiopathic Pulmonary Fibrosis Market Dynamics
2.3.1 Idiopathic Pulmonary Fibrosis Industry Trends
2.3.2 Idiopathic Pulmonary Fibrosis Market Drivers
2.3.3 Idiopathic Pulmonary Fibrosis Market Challenges
2.3.4 Idiopathic Pulmonary Fibrosis Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Idiopathic Pulmonary Fibrosis by Players
3.1.1 Global Idiopathic Pulmonary Fibrosis Revenue by Players (2018-2023)
3.1.2 Global Idiopathic Pulmonary Fibrosis Revenue Market Share by Players (2018-2023)
3.2 Global Idiopathic Pulmonary Fibrosis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Idiopathic Pulmonary Fibrosis, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Idiopathic Pulmonary Fibrosis Market Concentration Ratio
3.4.1 Global Idiopathic Pulmonary Fibrosis Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Idiopathic Pulmonary Fibrosis Revenue in 2022
3.5 Global Key Players of Idiopathic Pulmonary Fibrosis Head office and Area Served
3.6 Global Key Players of Idiopathic Pulmonary Fibrosis, Product and Application
3.7 Global Key Players of Idiopathic Pulmonary Fibrosis, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Idiopathic Pulmonary Fibrosis Breakdown Data by Type
4.1 Global Idiopathic Pulmonary Fibrosis Historic Market Size by Type (2018-2023)
4.2 Global Idiopathic Pulmonary Fibrosis Forecasted Market Size by Type (2024-2029)
5 Idiopathic Pulmonary Fibrosis Breakdown Data by Application
5.1 Global Idiopathic Pulmonary Fibrosis Historic Market Size by Application (2018-2023)
5.2 Global Idiopathic Pulmonary Fibrosis Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Idiopathic Pulmonary Fibrosis Market Size (2018-2029)
6.2 North America Idiopathic Pulmonary Fibrosis Market Size by Type
6.2.1 North America Idiopathic Pulmonary Fibrosis Market Size by Type (2018-2023)
6.2.2 North America Idiopathic Pulmonary Fibrosis Market Size by Type (2024-2029)
6.2.3 North America Idiopathic Pulmonary Fibrosis Market Share by Type (2018-2029)
6.3 North America Idiopathic Pulmonary Fibrosis Market Size by Application
6.3.1 North America Idiopathic Pulmonary Fibrosis Market Size by Application (2018-2023)
6.3.2 North America Idiopathic Pulmonary Fibrosis Market Size by Application (2024-2029)
6.3.3 North America Idiopathic Pulmonary Fibrosis Market Share by Application (2018-2029)
6.4 North America Idiopathic Pulmonary Fibrosis Market Size by Country
6.4.1 North America Idiopathic Pulmonary Fibrosis Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Idiopathic Pulmonary Fibrosis Market Size by Country (2018-2023)
6.4.3 North America Idiopathic Pulmonary Fibrosis Market Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Idiopathic Pulmonary Fibrosis Market Size (2018-2029)
7.2 Europe Idiopathic Pulmonary Fibrosis Market Size by Type
7.2.1 Europe Idiopathic Pulmonary Fibrosis Market Size by Type (2018-2023)
7.2.2 Europe Idiopathic Pulmonary Fibrosis Market Size by Type (2024-2029)
7.2.3 Europe Idiopathic Pulmonary Fibrosis Market Share by Type (2018-2029)
7.3 Europe Idiopathic Pulmonary Fibrosis Market Size by Application
7.3.1 Europe Idiopathic Pulmonary Fibrosis Market Size by Application (2018-2023)
7.3.2 Europe Idiopathic Pulmonary Fibrosis Market Size by Application (2024-2029)
7.3.3 Europe Idiopathic Pulmonary Fibrosis Market Share by Application (2018-2029)
7.4 Europe Idiopathic Pulmonary Fibrosis Market Size by Country
7.4.1 Europe Idiopathic Pulmonary Fibrosis Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Idiopathic Pulmonary Fibrosis Market Size by Country (2018-2023)
7.4.3 Europe Idiopathic Pulmonary Fibrosis Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Idiopathic Pulmonary Fibrosis Market Size (2018-2029)
8.2 China Idiopathic Pulmonary Fibrosis Market Size by Type
8.2.1 China Idiopathic Pulmonary Fibrosis Market Size by Type (2018-2023)
8.2.2 China Idiopathic Pulmonary Fibrosis Market Size by Type (2024-2029)
8.2.3 China Idiopathic Pulmonary Fibrosis Market Share by Type (2018-2029)
8.3 China Idiopathic Pulmonary Fibrosis Market Size by Application
8.3.1 China Idiopathic Pulmonary Fibrosis Market Size by Application (2018-2023)
8.3.2 China Idiopathic Pulmonary Fibrosis Market Size by Application (2024-2029)
8.3.3 China Idiopathic Pulmonary Fibrosis Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Idiopathic Pulmonary Fibrosis Market Size (2018-2029)
9.2 Asia Idiopathic Pulmonary Fibrosis Market Size by Type
9.2.1 Asia Idiopathic Pulmonary Fibrosis Market Size by Type (2018-2023)
9.2.2 Asia Idiopathic Pulmonary Fibrosis Market Size by Type (2024-2029)
9.2.3 Asia Idiopathic Pulmonary Fibrosis Market Share by Type (2018-2029)
9.3 Asia Idiopathic Pulmonary Fibrosis Market Size by Application
9.3.1 Asia Idiopathic Pulmonary Fibrosis Market Size by Application (2018-2023)
9.3.2 Asia Idiopathic Pulmonary Fibrosis Market Size by Application (2024-2029)
9.3.3 Asia Idiopathic Pulmonary Fibrosis Market Share by Application (2018-2029)
9.4 Asia Idiopathic Pulmonary Fibrosis Market Size by Region
9.4.1 Asia Idiopathic Pulmonary Fibrosis Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Idiopathic Pulmonary Fibrosis Market Size by Region (2018-2023)
9.4.3 Asia Idiopathic Pulmonary Fibrosis Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Idiopathic Pulmonary Fibrosis Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Idiopathic Pulmonary Fibrosis Market Size by Type
10.2.1 Middle East, Africa, and Latin America Idiopathic Pulmonary Fibrosis Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Idiopathic Pulmonary Fibrosis Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Idiopathic Pulmonary Fibrosis Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Idiopathic Pulmonary Fibrosis Market Size by Application
10.3.1 Middle East, Africa, and Latin America Idiopathic Pulmonary Fibrosis Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Idiopathic Pulmonary Fibrosis Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Idiopathic Pulmonary Fibrosis Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Idiopathic Pulmonary Fibrosis Market Size by Country
10.4.1 Middle East, Africa, and Latin America Idiopathic Pulmonary Fibrosis Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Idiopathic Pulmonary Fibrosis Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Idiopathic Pulmonary Fibrosis Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 MediciNova
11.1.1 MediciNova Company Details
11.1.2 MediciNova Business Overview
11.1.3 MediciNova Idiopathic Pulmonary Fibrosis Introduction
11.1.4 MediciNova Revenue in Idiopathic Pulmonary Fibrosis Business (2018-2023)
11.1.5 MediciNova Recent Developments
11.2 Boehringer Ingelheim
11.2.1 Boehringer Ingelheim Company Details
11.2.2 Boehringer Ingelheim Business Overview
11.2.3 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Introduction
11.2.4 Boehringer Ingelheim Revenue in Idiopathic Pulmonary Fibrosis Business (2018-2023)
11.2.5 Boehringer Ingelheim Recent Developments
11.3 F. Hoffmann-La Roche
11.3.1 F. Hoffmann-La Roche Company Details
11.3.2 F. Hoffmann-La Roche Business Overview
11.3.3 F. Hoffmann-La Roche Idiopathic Pulmonary Fibrosis Introduction
11.3.4 F. Hoffmann-La Roche Revenue in Idiopathic Pulmonary Fibrosis Business (2018-2023)
11.3.5 F. Hoffmann-La Roche Recent Developments
11.4 FibroGen
11.4.1 FibroGen Company Details
11.4.2 FibroGen Business Overview
11.4.3 FibroGen Idiopathic Pulmonary Fibrosis Introduction
11.4.4 FibroGen Revenue in Idiopathic Pulmonary Fibrosis Business (2018-2023)
11.4.5 FibroGen Recent Developments
11.5 Promedior
11.5.1 Promedior Company Details
11.5.2 Promedior Business Overview
11.5.3 Promedior Idiopathic Pulmonary Fibrosis Introduction
11.5.4 Promedior Revenue in Idiopathic Pulmonary Fibrosis Business (2018-2023)
11.5.5 Promedior Recent Developments
11.6 Merck
11.6.1 Merck Company Details
11.6.2 Merck Business Overview
11.6.3 Merck Idiopathic Pulmonary Fibrosis Introduction
11.6.4 Merck Revenue in Idiopathic Pulmonary Fibrosis Business (2018-2023)
11.6.5 Merck Recent Developments
11.7 Galapagos
11.7.1 Galapagos Company Details
11.7.2 Galapagos Business Overview
11.7.3 Galapagos Idiopathic Pulmonary Fibrosis Introduction
11.7.4 Galapagos Revenue in Idiopathic Pulmonary Fibrosis Business (2018-2023)
11.7.5 Galapagos Recent Developments
11.8 Prometic Life Sciences
11.8.1 Prometic Life Sciences Company Details
11.8.2 Prometic Life Sciences Business Overview
11.8.3 Prometic Life Sciences Idiopathic Pulmonary Fibrosis Introduction
11.8.4 Prometic Life Sciences Revenue in Idiopathic Pulmonary Fibrosis Business (2018-2023)
11.8.5 Prometic Life Sciences Recent Developments
11.9 Cipla
11.9.1 Cipla Company Details
11.9.2 Cipla Business Overview
11.9.3 Cipla Idiopathic Pulmonary Fibrosis Introduction
11.9.4 Cipla Revenue in Idiopathic Pulmonary Fibrosis Business (2018-2023)
11.9.5 Cipla Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Idiopathic Pulmonary Fibrosis Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
    Table 2. Key Players of Systemic Corticosteroids
    Table 3. Key Players of Immunosuppressant Drugs
    Table 4. Key Players of Tyrosine Kinase Inhibitors
    Table 5. Key Players of Antifibrotic Agents
    Table 6. Global Idiopathic Pulmonary Fibrosis Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
    Table 7. Global Idiopathic Pulmonary Fibrosis Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 8. Global Idiopathic Pulmonary Fibrosis Market Size by Region (2018-2023) & (US$ Million)
    Table 9. Global Idiopathic Pulmonary Fibrosis Market Share by Region (2018-2023)
    Table 10. Global Idiopathic Pulmonary Fibrosis Forecasted Market Size by Region (2024-2029) & (US$ Million)
    Table 11. Global Idiopathic Pulmonary Fibrosis Market Share by Region (2024-2029)
    Table 12. Idiopathic Pulmonary Fibrosis Market Trends
    Table 13. Idiopathic Pulmonary Fibrosis Market Drivers
    Table 14. Idiopathic Pulmonary Fibrosis Market Challenges
    Table 15. Idiopathic Pulmonary Fibrosis Market Restraints
    Table 16. Global Idiopathic Pulmonary Fibrosis Revenue by Players (2018-2023) & (US$ Million)
    Table 17. Global Idiopathic Pulmonary Fibrosis Revenue Share by Players (2018-2023)
    Table 18. Global Top Idiopathic Pulmonary Fibrosis by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Idiopathic Pulmonary Fibrosis as of 2022)
    Table 19. Global Idiopathic Pulmonary Fibrosis Industry Ranking 2021 VS 2022 VS 2023
    Table 20. Global 5 Largest Players Market Share by Idiopathic Pulmonary Fibrosis Revenue (CR5 and HHI) & (2018-2023)
    Table 21. Global Key Players of Idiopathic Pulmonary Fibrosis, Headquarters and Area Served
    Table 22. Global Key Players of Idiopathic Pulmonary Fibrosis, Product and Application
    Table 23. Global Key Players of Idiopathic Pulmonary Fibrosis, Product and Application
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Idiopathic Pulmonary Fibrosis Market Size by Type (2018-2023) & (US$ Million)
    Table 26. Global Idiopathic Pulmonary Fibrosis Revenue Market Share by Type (2018-2023)
    Table 27. Global Idiopathic Pulmonary Fibrosis Forecasted Market Size by Type (2024-2029) & (US$ Million)
    Table 28. Global Idiopathic Pulmonary Fibrosis Revenue Market Share by Type (2024-2029)
    Table 29. Global Idiopathic Pulmonary Fibrosis Market Size by Application (2018-2023) & (US$ Million)
    Table 30. Global Idiopathic Pulmonary Fibrosis Revenue Share by Application (2018-2023)
    Table 31. Global Idiopathic Pulmonary Fibrosis Forecasted Market Size by Application (2024-2029) & (US$ Million)
    Table 32. Global Idiopathic Pulmonary Fibrosis Revenue Share by Application (2024-2029)
    Table 33. North America Idiopathic Pulmonary Fibrosis Market Size by Type (2018-2023) & (US$ Million)
    Table 34. North America Idiopathic Pulmonary Fibrosis Market Size by Type (2024-2029) & (US$ Million)
    Table 35. North America Idiopathic Pulmonary Fibrosis Market Size by Application (2018-2023) & (US$ Million)
    Table 36. North America Idiopathic Pulmonary Fibrosis Market Size by Application (2024-2029) & (US$ Million)
    Table 37. North America Idiopathic Pulmonary Fibrosis Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 38. North America Idiopathic Pulmonary Fibrosis Market Size by Country (2018-2023) & (US$ Million)
    Table 39. North America Idiopathic Pulmonary Fibrosis Market Size by Country (2024-2029) & (US$ Million)
    Table 40. Europe Idiopathic Pulmonary Fibrosis Market Size by Type (2018-2023) & (US$ Million)
    Table 41. Europe Idiopathic Pulmonary Fibrosis Market Size by Type (2024-2029) & (US$ Million)
    Table 42. Europe Idiopathic Pulmonary Fibrosis Market Size by Application (2018-2023) & (US$ Million)
    Table 43. Europe Idiopathic Pulmonary Fibrosis Market Size by Application (2024-2029) & (US$ Million)
    Table 44. Europe Idiopathic Pulmonary Fibrosis Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 45. Europe Idiopathic Pulmonary Fibrosis Market Size by Country (2018-2023) & (US$ Million)
    Table 46. Europe Idiopathic Pulmonary Fibrosis Market Size by Country (2024-2029) & (US$ Million)
    Table 47. China Idiopathic Pulmonary Fibrosis Market Size by Type (2018-2023) & (US$ Million)
    Table 48. China Idiopathic Pulmonary Fibrosis Market Size by Type (2024-2029) & (US$ Million)
    Table 49. China Idiopathic Pulmonary Fibrosis Market Size by Application (2018-2023) & (US$ Million)
    Table 50. China Idiopathic Pulmonary Fibrosis Market Size by Application (2024-2029) & (US$ Million)
    Table 51. Asia Idiopathic Pulmonary Fibrosis Market Size by Type (2018-2023) & (US$ Million)
    Table 52. Asia Idiopathic Pulmonary Fibrosis Market Size by Type (2024-2029) & (US$ Million)
    Table 53. Asia Idiopathic Pulmonary Fibrosis Market Size by Application (2018-2023) & (US$ Million)
    Table 54. Asia Idiopathic Pulmonary Fibrosis Market Size by Application (2024-2029) & (US$ Million)
    Table 55. Asia Idiopathic Pulmonary Fibrosis Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 56. Asia Idiopathic Pulmonary Fibrosis Market Size by Region (2018-2023) & (US$ Million)
    Table 57. Asia Idiopathic Pulmonary Fibrosis Market Size by Region (2024-2029) & (US$ Million)
    Table 58. Middle East, Africa, and Latin America Idiopathic Pulmonary Fibrosis Market Size by Type (2018-2023) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Idiopathic Pulmonary Fibrosis Market Size by Type (2024-2029) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Idiopathic Pulmonary Fibrosis Market Size by Application (2018-2023) & (US$ Million)
    Table 61. Middle East, Africa, and Latin America Idiopathic Pulmonary Fibrosis Market Size by Application (2024-2029) & (US$ Million)
    Table 62. Middle East, Africa, and Latin America Idiopathic Pulmonary Fibrosis Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 63. Middle East, Africa, and Latin America Idiopathic Pulmonary Fibrosis Market Size by Country (2018-2023) & (US$ Million)
    Table 64. Middle East, Africa, and Latin America Idiopathic Pulmonary Fibrosis Market Size by Country (2024-2029) & (US$ Million)
    Table 65. MediciNova Company Details
    Table 66. MediciNova Business Overview
    Table 67. MediciNova Idiopathic Pulmonary Fibrosis Product
    Table 68. MediciNova Revenue in Idiopathic Pulmonary Fibrosis Business (2018-2023) & (US$ Million)
    Table 69. MediciNova Recent Developments
    Table 70. Boehringer Ingelheim Company Details
    Table 71. Boehringer Ingelheim Business Overview
    Table 72. Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Product
    Table 73. Boehringer Ingelheim Revenue in Idiopathic Pulmonary Fibrosis Business (2018-2023) & (US$ Million)
    Table 74. Boehringer Ingelheim Recent Developments
    Table 75. F. Hoffmann-La Roche Company Details
    Table 76. F. Hoffmann-La Roche Business Overview
    Table 77. F. Hoffmann-La Roche Idiopathic Pulmonary Fibrosis Product
    Table 78. F. Hoffmann-La Roche Revenue in Idiopathic Pulmonary Fibrosis Business (2018-2023) & (US$ Million)
    Table 79. F. Hoffmann-La Roche Recent Developments
    Table 80. FibroGen Company Details
    Table 81. FibroGen Business Overview
    Table 82. FibroGen Idiopathic Pulmonary Fibrosis Product
    Table 83. FibroGen Revenue in Idiopathic Pulmonary Fibrosis Business (2018-2023) & (US$ Million)
    Table 84. FibroGen Recent Developments
    Table 85. Promedior Company Details
    Table 86. Promedior Business Overview
    Table 87. Promedior Idiopathic Pulmonary Fibrosis Product
    Table 88. Promedior Revenue in Idiopathic Pulmonary Fibrosis Business (2018-2023) & (US$ Million)
    Table 89. Promedior Recent Developments
    Table 90. Merck Company Details
    Table 91. Merck Business Overview
    Table 92. Merck Idiopathic Pulmonary Fibrosis Product
    Table 93. Merck Revenue in Idiopathic Pulmonary Fibrosis Business (2018-2023) & (US$ Million)
    Table 94. Merck Recent Developments
    Table 95. Galapagos Company Details
    Table 96. Galapagos Business Overview
    Table 97. Galapagos Idiopathic Pulmonary Fibrosis Product
    Table 98. Galapagos Revenue in Idiopathic Pulmonary Fibrosis Business (2018-2023) & (US$ Million)
    Table 99. Galapagos Recent Developments
    Table 100. Prometic Life Sciences Company Details
    Table 101. Prometic Life Sciences Business Overview
    Table 102. Prometic Life Sciences Idiopathic Pulmonary Fibrosis Product
    Table 103. Prometic Life Sciences Revenue in Idiopathic Pulmonary Fibrosis Business (2018-2023) & (US$ Million)
    Table 104. Prometic Life Sciences Recent Developments
    Table 105. Cipla Company Details
    Table 106. Cipla Business Overview
    Table 107. Cipla Idiopathic Pulmonary Fibrosis Product
    Table 108. Cipla Revenue in Idiopathic Pulmonary Fibrosis Business (2018-2023) & (US$ Million)
    Table 109. Cipla Recent Developments
    Table 110. Research Programs/Design for This Report
    Table 111. Key Data Information from Secondary Sources
    Table 112. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Idiopathic Pulmonary Fibrosis Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
    Figure 2. Global Idiopathic Pulmonary Fibrosis Market Share by Type: 2022 VS 2029
    Figure 3. Systemic Corticosteroids Features
    Figure 4. Immunosuppressant Drugs Features
    Figure 5. Tyrosine Kinase Inhibitors Features
    Figure 6. Antifibrotic Agents Features
    Figure 7. Global Idiopathic Pulmonary Fibrosis Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
    Figure 8. Global Idiopathic Pulmonary Fibrosis Market Share by Application: 2022 VS 2029
    Figure 9. Hospitals Case Studies
    Figure 10. Clinics Case Studies
    Figure 11. Ambulatory Surgical Centers Case Studies
    Figure 12. Academic and Research Organizations Case Studies
    Figure 13. Idiopathic Pulmonary Fibrosis Report Years Considered
    Figure 14. Global Idiopathic Pulmonary Fibrosis Market Size (US$ Million), Year-over-Year: 2018-2029
    Figure 15. Global Idiopathic Pulmonary Fibrosis Market Size, (US$ Million), 2018 VS 2022 VS 2029
    Figure 16. Global Idiopathic Pulmonary Fibrosis Market Share by Region: 2022 VS 2029
    Figure 17. Global Idiopathic Pulmonary Fibrosis Market Share by Players in 2022
    Figure 18. Global Top Idiopathic Pulmonary Fibrosis Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Idiopathic Pulmonary Fibrosis as of 2022)
    Figure 19. The Top 10 and 5 Players Market Share by Idiopathic Pulmonary Fibrosis Revenue in 2022
    Figure 20. North America Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 21. North America Idiopathic Pulmonary Fibrosis Market Share by Type (2018-2029)
    Figure 22. North America Idiopathic Pulmonary Fibrosis Market Share by Application (2018-2029)
    Figure 23. North America Idiopathic Pulmonary Fibrosis Market Share by Country (2018-2029)
    Figure 24. United States Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 25. Canada Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 26. Europe Idiopathic Pulmonary Fibrosis Market Size YoY (2018-2029) & (US$ Million)
    Figure 27. Europe Idiopathic Pulmonary Fibrosis Market Share by Type (2018-2029)
    Figure 28. Europe Idiopathic Pulmonary Fibrosis Market Share by Application (2018-2029)
    Figure 29. Europe Idiopathic Pulmonary Fibrosis Market Share by Country (2018-2029)
    Figure 30. Germany Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 31. France Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 32. U.K. Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 33. Italy Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 34. Russia Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 35. Nordic Countries Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 36. China Idiopathic Pulmonary Fibrosis Market Size YoY (2018-2029) & (US$ Million)
    Figure 37. China Idiopathic Pulmonary Fibrosis Market Share by Type (2018-2029)
    Figure 38. China Idiopathic Pulmonary Fibrosis Market Share by Application (2018-2029)
    Figure 39. Asia Idiopathic Pulmonary Fibrosis Market Size YoY (2018-2029) & (US$ Million)
    Figure 40. Asia Idiopathic Pulmonary Fibrosis Market Share by Type (2018-2029)
    Figure 41. Asia Idiopathic Pulmonary Fibrosis Market Share by Application (2018-2029)
    Figure 42. Asia Idiopathic Pulmonary Fibrosis Market Share by Region (2018-2029)
    Figure 43. Japan Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 44. South Korea Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 45. China Taiwan Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 46. Southeast Asia Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 47. India Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 48. Australia Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 49. Middle East, Africa, and Latin America Idiopathic Pulmonary Fibrosis Market Size YoY (2018-2029) & (US$ Million)
    Figure 50. Middle East, Africa, and Latin America Idiopathic Pulmonary Fibrosis Market Share by Type (2018-2029)
    Figure 51. Middle East, Africa, and Latin America Idiopathic Pulmonary Fibrosis Market Share by Application (2018-2029)
    Figure 52. Middle East, Africa, and Latin America Idiopathic Pulmonary Fibrosis Market Share by Country (2018-2029)
    Figure 53. Brazil Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 54. Mexico Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 55. Turkey Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 56. Saudi Arabia Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 57. Israel Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 58. GCC Countries Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 59. MediciNova Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2018-2023)
    Figure 60. Boehringer Ingelheim Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2018-2023)
    Figure 61. F. Hoffmann-La Roche Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2018-2023)
    Figure 62. FibroGen Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2018-2023)
    Figure 63. Promedior Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2018-2023)
    Figure 64. Merck Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2018-2023)
    Figure 65. Galapagos Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2018-2023)
    Figure 66. Prometic Life Sciences Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2018-2023)
    Figure 67. Cipla Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2018-2023)
    Figure 68. Bottom-up and Top-down Approaches for This Report
    Figure 69. Data Triangulation
    Figure 70. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Nitric Oxide Asthma Testing Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-9B6080
Fri Jul 12 00:00:00 UTC 2024

Add to Cart

Global Dyspnea Treatment Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-4H6109
Tue Jun 11 00:00:00 UTC 2024

Add to Cart

Human Respiratory Disease Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-26I9547
Mon Jun 10 00:00:00 UTC 2024

Add to Cart

Global Spirometer Paper Mouthpiece Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-19H17456
Mon Jun 10 00:00:00 UTC 2024

Add to Cart